Related Experiment Video
Updated: May 9, 2026
A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
Published on: October 16, 2015
Structural studies of several clinically important oncology drugs in complex with human serum albumin
Zhong-min Wang1, Joseph X Ho, John R Ruble
1New Century Pharmaceuticals, Inc., 895 Martin Road, Suite C, Huntsville, AL 35824, USA.
Background:
Serum albumin is a major pharmacokinetic effector of drugs. To gain further insight into albumin binding chemistry, the crystal structures of six oncology agents were determined in complex with human serum albumin at resolutions of 2.8 to 2.0Å: camptothecin, 9-amino-camptothecin, etoposide, teniposide, bicalutamide and idarubicin.
Methods:
Protein crystal growth and low temperature X-ray crystallography
Results:
These large, complex drugs are all bound within the subdomain IB binding region which can be described as a hydrophobic groove formed by α-helices h7, h8 and h9 covered by the extended polypeptide L1. L1 creates a binding cavity with two access sites, one between loop L1 and α-helices h7 and h8 (distal site: IBd) and the other between L1 and α-helix h9 (proximal site: IBp). Camptothecin (2.4Å) and 9 amino camptothecin (2.0Å) are clearly bound as the open lactone form (IBp). Idarubicin (2.8Å) binds in a DNA like dimer complex via an intermolecular π stacking arrangement in IBd. Bicalutamide (2.4Å) is bound in a folded intramolecular π stacking arrangement between two aromatic rings in IBd similar to idarubicin. Teniposide (2.7Å) and etoposide (2.7Å), despite small chemical differences, are bound in two distinctly different sites at or near IB. Teniposide is internalized via primarily hydrophobic interactions and spans through both openings (IBp-d). Etoposide is bound between the exterior of IB and IIA and exhibits an extensive hydrogen bonding network.
Conclusions:
Subdomain IB is a major binding site for complex heterocyclic molecules.
General Significance:
The structures have important implications for drug design and development. This article is part of a Special Issue entitled Serum Albumin.
Insights
Crystal structures reveal that human serum albumin subdomain IB is a key binding site for complex oncology drugs. These findings offer critical insights for designing more effective cancer therapies.
Area of Science:
- Pharmacology and structural biology
- Drug discovery and development
Background:
- Serum albumin is a critical pharmacokinetic effector influencing drug behavior.
- Understanding albumin binding chemistry is essential for optimizing drug efficacy.
Purpose of the Study:
- To elucidate the binding interactions of six oncology agents with human serum albumin.
- To determine the structural basis of drug binding within albumin.
Main Methods:
- Protein crystal growth and low-temperature X-ray crystallography were employed.
- High-resolution structural data (2.0–2.8Å) were obtained for drug-albumin complexes.
Main Results:
- Six oncology drugs (camptothecin, 9-amino-camptothecin, etoposide, teniposide, bicalutamide, idarubicin) bind to subdomain IB.
- Specific binding modes were identified, including interactions within hydrophobic grooves and distinct access sites (IBd and IBp).
- Drug binding involves diverse interactions such as lactone ring conformation, π-stacking, hydrophobic interactions, and hydrogen bonding networks.
Conclusions:
- Subdomain IB of human serum albumin serves as a primary binding site for complex heterocyclic drug molecules.
- The determined structures provide valuable structural information for rational drug design and development of novel therapeutics.
Related Concept Videos
01:29Drug Distribution: Plasma Protein Binding
01:30Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be bound by...
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:21Drug Distribution: Tissue Binding
For...